Cytodyn: Funding, Investors & Team (Nov 2026)
CytoDyn is a biotechnology company focused on the development of new therapies to combat infections with immune deficiency viruses. It has a unique and once-in-a-lifetime opportunity to possibly impact the IV/AIDS problem facing the world. CytoDyn will diligently pursue science and business opportunities, as presented, that may eventually benefit both shareholders and the world. CytoDyn developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The company intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. They conducting a Phase 1b/2 clinical trial to evaluate its targeted therapy for the treatment of metastatic triple-negative breast cancer, the most aggressive type of breast cancer.
Cytodyn has raised $17.5M across 1 funding round on record, the most recent an undisclosed round of $17.5M announced in Mar 2026.
That round is above the $8.9M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cytodyn Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Cytodyn Funding Rounds
Cytodyn Founders and Leadership Team
Contact details for the Cytodyn team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Cytodyn Funding Compared to Other Biotechnology Startups
Cytodyn's latest round of $17.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cytodyn in Biotechnology and Vancouver
Companies Similar to Cytodyn
Araceli Biosciences specializes in creating scientific instruments for discovering tissue- and cell-based…
Switchpoint Bio is a biotechnology company that offers immune relevant drug treatments.
Nanopath Inc. is a company that specializes in molecular diagnostics and allows for fast, high-quality…
Frontier Bio is creating lab-grown human tissues as an ethical replacement for animal studies and is setting…
Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel…
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus…
Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Cytodyn Funding FAQs
What does Cytodyn do?
CytoDyn is a biotechnology company focused on the development of new therapies to combat infections with immune deficiency viruses. It has a unique and once-in-a-lifetime opportunity to possibly impact the IV/AIDS problem facing the world. CytoDyn will diligently pursue science and business opportunities, as presented, that may eventually benefit both shareholders and the world. CytoDyn developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The company intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. They conducting a Phase 1b/2 clinical trial to evaluate its targeted therapy for the treatment of metastatic triple-negative breast cancer, the most aggressive type of breast cancer.
How much funding has Cytodyn raised?
Cytodyn has raised $17.5M across 1 round on record. The most recent is an undisclosed round of $17.5M announced in Mar 2026.
When did Cytodyn last raise funding?
Cytodyn's most recent funding round on record is an undisclosed round of $17.5M, announced in Mar 2026.
Who founded Cytodyn?
FundedIQ lists Jay Lalezari (Founder) at Cytodyn.
Where is Cytodyn headquartered?
Cytodyn is based in Vancouver, Washington, United States.
How many employees does Cytodyn have?
Cytodyn is in the 11-50 employee band.
How does Cytodyn's funding compare to other Biotechnology startups?
Cytodyn's latest round of $17.5M is above the $8.9M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.
About FundedIQ's Cytodyn Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cytodyn is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.